ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

EU · CHMP positive opinion: new indication

Enfortumab vedotin (Padcev)

New indication (Carcinoma, Transitional Cell, Urologic Neoplasms). The wording is on the EMA page.

CHMP opinion 21 May 2026 · Astellas Pharma Europe B.V.

Research

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.